Tuesday, June 20, 2023

We Don't Have to Trade With China

But people have their rea$on$:

**

**

**

Just to remind one that neither Yuen Pau Woo and Victor Oh support this country.

But don't take my word for it:

 

We can certainly trust the immigration department to do its due diligence, right?

Oh, wait!:

Nearly half of foreign nationals flagged by security agencies to the Immigration Department for ties to serious offences including war crimes, espionage and terrorism were allowed to take up residency in Canada between 2014 and 2019.

An internal audit of the Immigration National Security Screening Program found that immigration officials ultimately approved temporary or permanent residency, or refugee applications for 46 per cent of the more than 7,000 cases where the Canadian Border Security Agency (CBSA) recommended against applicants being allowed into the country.

“That’s super concerning. It means that there’s a disconnect between the partner agencies engaged in the processing of foreign nationals seeking entry into Canada. It’s really alarming,” said criminologist and former longtime border services officer Kelly Sundberg.

The data are contained in an internal audit quietly published earlier this year by the CBSA, which was to assess the effectiveness and efficiency of the country’s Immigration National Security Screening Program between 2014 and 2019.

The program is run by CBSA’s national security screening division, often in collaboration with the Canadian Security Intelligence Service (CSIS). Its goal is to “prevent inadmissible foreign nationals or permanent residents from entering or remaining in Canada,” according to the audit.

To do so, security screeners review temporary or permanent residence applications or refugee claims flagged by Immigration, Refugees and Citizenship Canada (IRCC) as posing a potential security risk.

Screeners then assess the potential inadmissibility of applicants under sections of the Immigration and Refugee Protection Act that deal with serious crimes such as espionage, terrorism, crimes against humanity, or organized criminality, and then submit a recommendation to IRCC officers.

**

Global consulting giant McKinsey & Co., under the leadership of Dominic Barton, pitched Purdue Pharma (Canada) in 2014 on how it could more aggressively market and boost sales of OxyContin and other highly addictive opioids to Canadians, according to a confidential memo obtained by The Globe and Mail.

McKinsey & Co. is facing a class-action lawsuit from the B.C. government, which Ottawa plans to join, that accuses the firm of engaging in reckless marketing campaigns to boost opioid sales, placing the Liberal government at odds with a company it has relied on for more than $100-million in contract work since 2015.

Mr. Barton became a pro-bono economic adviser to Prime Minister Justin Trudeau when the Liberals formed government in 2015 and was later named Canada’s ambassador to China in 2019. Since 2015, the total value of federal contracts awarded to McKinsey has risen to at least $116.8-million, spanning several federal departments. McKinsey has said in court filings that its contracts with Ottawa make up as much as 10 per cent of its gross revenue in Canada.

In recent testimony before parliamentary committees examining those contracts, Mr. Barton, who resigned as envoy to Beijing in December, 2021, to become chairman of Rio Tinto, and Robert Palter, managing partner of McKinsey’s Canadian office, stated the consulting firm has done “no opioid sales and marketing in Canada.”

What the two men did not mention was that McKinsey pitched Purdue Pharma (Canada) to do exactly that on March 18, 2014. A McKinsey memo to Purdue, titled Identifying Growth Opportunities in Canada, states: “We appreciate your interest in driving sales growth and look forward to supporting you.”

The memo to Purdue Pharma (Canada) president Craig Landau went on to say McKinsey was seeking to identify three to five near-term “revenue acceleration activities” for the 2014-2015 period.

It described how McKinsey could help Purdue determine whether there are opportunities to “better target and reach high-potential prescribers” and increase the motivation of Purdue’s pharmaceutical sales representatives by analyzing “what opportunities exist to change incentive compensation to better align the sales force goals to company objectives.”

The Globe and Mail obtained the memo and other records from the Opioid Industry Documents Archive, a searchable online collection of 1.5 million documents collected as a result of litigation against the U.S. pharmaceutical industry. The archive at the University of California, San Francisco and Johns Hopkins University includes more than 114,000 documents from McKinsey, which consulted on opioid sales and marketing for Purdue Pharma in the United States.

Other documents from the archives show e-mail exchanges in December, 2015, between McKinsey consultant Ankit Saxena and Purdue Pharma (Canada)’s then-director of finance Rajeev Bhatt in which they discuss a 2020 gross sales forecast for products such as OxyContin, Codeine Contin, OxyNeo and Hysingla as part of a “strategic evaluation.” There are also documents dated as far back as 2013 when McKinsey consultants talk about working with Purdue, shortly after Mr. Landau took over as Purdue Pharma (Canada) CEO.

 


Posted by at
Labels: , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)